Claris Genomics

Oncology

Overview

Claris Genomiccs is delivering the first-to-market colon cancer diagnostic test that sub-types a patient’s colon cancer in a way that better personalizes a patient's treatment plan. The test, ColotypeR, is expected to improve patient outcomes and health economics while avoiding costly overtreatment. The firm is based off of technology from Steven Buechler, a professor in applied and computational mathematics and statistics; Yesim Gokman-Polarp and Amanda Hummon, an adjunct associate professor in chemistry and biochemistry.

Founder(s)

Jeff Sayre

Contact

jeff@thirdspan.com
Visit Claris Genomics website